肺がん診断およびスクリーニングの世界市場レポート 2025年

肺がん診断およびスクリーニング市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.5％で36億9,000万米ドルに成長します。予測期間の成長は、肺がん罹患率の増加、早期発見の重視の高まり、高リスク検診プログラムの拡大、個別化医療へのシフト、政府の取り組み、資金調達などに起因すると考えられます。予測期間における主な動向には、新規スクリーニング法の出現、バイオマーカー検査の進歩、人工知能（AI）の統合、リキッドバイオプシー採用の増加、早期発見の重視、低線量CTスクリーニングプログラムの拡大などがあります。

肺がんの有病率の増加が予測され、当面の肺がん診断およびスクリーニング市場の成長を牽引する見通しです。咳、胸痛、呼吸困難などの症状を特徴とする肺がんは、肺組織における異常細胞の無秩序な増殖によって特徴づけられる悪性疾患です。肺がんの診断およびスクリーニング方法は、早期発見において重要な役割を果たし、切開生検や気管支鏡検査などの様々な検査が利用されています。2023年1月現在、米国がん協会のデータによると、米国では約238,340人が新たに肺がんに罹患し、127,070人が死亡したと報告されています。この肺がん症例の急増は、診断およびスクリーニング対策の重要性を強調し、肺がん診断およびスクリーニング市場の成長に拍車をかけています。

ヘルスケア支出の増加は、肺がん診断およびスクリーニング市場の拡大をさらに促進すると予測されています。ヘルスケア支出は、医療サービス、治療、ヘルスケア関連商品や活動の提供や受領に関連する総費用を包括します。肺がん診断およびスクリーニングの導入は、早期発見、長期的な治療費の削減、患者の転帰の改善により、ヘルスケア支出に貢献します。2022年11月、カナダ保健情報研究所（CIHI）は、カナダの総医療費が0.8％増加し、2021年の3,280億米ドルから2022年には3,310億米ドルに達すると予測しました。このような医療支出の増加傾向は、肺がん診断およびスクリーニング市場の成長における重要な促進要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肺がん診断およびスクリーニング PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の肺がん診断およびスクリーニング市場：成長率分析
• 世界の肺がん診断およびスクリーニング市場の実績：規模と成長, 2019-2024
• 世界の肺がん診断およびスクリーニング市場の予測：規模と成長, 2024-2029, 2034F
• 世界の肺がん診断およびスクリーニング総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の肺がん診断およびスクリーニング市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機器
• 消耗品および付属品
• 世界の肺がん診断およびスクリーニング市場：検査別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオマーカー検査
• 画像検査
• 生検
• 血液検査
• その他の検査
• 世界の肺がん診断およびスクリーニング市場：がんタイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非小細胞肺がん
• 小細胞肺がん
• 世界の肺がん診断およびスクリーニング市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 独立診断研究所
• 画像診断センター
• がん研究機関
• その他のエンドユーザー
• 世界の肺がん診断およびスクリーニング市場、タイプ別サブセグメンテーション：機器、実績と予測, 2019-2024, 2024-2029F, 2034F
• イメージングデバイス
• 生検装置
• 気管支鏡検査システム
• 世界の肺がん診断およびスクリーニング市場、タイプ別サブセグメンテーション：消耗品および付属品、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生検針
• 試薬とアッセイ
• 画像造影剤
• 患者準備機器
• サンプル収集キット
• 実験用品

第7章 地域別・国別分析

• 世界の肺がん診断およびスクリーニング市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肺がん診断およびスクリーニング市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺がん診断およびスクリーニング市場：競合情勢
• 肺がん診断およびスクリーニング市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories Inc.
• Danaher Corporation
• Siemens Healthcare GmbH
• FUJIFILM Corporation
• Koninklijke Philips N.V.
• GE Healthcare Bio Sciences AB
• Quest Diagnostics Incorporated
• Agilent Technologies Inc.
• Illumina Inc.
• Qiagen Inc.
• Myriad Genetic Laboratories Inc.
• NeoGenomics Laboratories Inc.
• Canon Medical Systems Corporation
• OncimmuneHoldings Plc
• Broncus Medical Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肺がん診断およびスクリーニング市場2029：新たな機会を提供する国
• 肺がん診断およびスクリーニング市場2029：新たな機会を提供するセグメント
• 肺がん診断およびスクリーニング市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lung cancer diagnosis and screening involve employing examinations and techniques to detect and identify lung cancer, aiming for early detection and accurate diagnosis to facilitate effective treatment planning. This process is commonly applied in the treatment of squamous cell carcinomas, adenocarcinoma, and large cell carcinoma.

The primary products associated with lung cancer diagnostics and screening include instruments, consumables, and accessories. Instruments are products utilized to analyze the results of diagnostic tests and process samples for diagnostic purposes. Various tests, such as biomarker tests, imaging tests, biopsy, and blood tests, are employed for different cancer types, including non-small cell lung cancer and small cell lung cancer. These diagnostic tools find application across diverse end-users, including hospitals, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.

The lung cancer diagnostics and screening market research report are one of a series of new reports from The Business Research Company that provides lung cancer diagnostics and screening market statistics, including lung cancer diagnostics and screening industry global market size, regional shares, competitors with a lung cancer diagnostics and screening market share, detailed lung cancer diagnostics and screening market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer diagnostics and screening industry. This lung cancer diagnostics and screening market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lung cancer diagnostic and screening market size has grown strongly in recent years. It will grow from $2.34 billion in 2024 to $2.56 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to growth in digital imaging, standardization of screening protocols, public health initiatives against tobacco use, establishment of cancer registries, and advancements in pathology analysis

The lung cancer diagnostic and screening market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to increasing incidence of lung cancer, growing emphasis on early detection, expansion of high-risk screening programs, shift towards personalized medicine, government initiatives and funding. Major trends in the forecast period include emergence of novel screening modalities, advancements in biomarker testing, integration of artificial intelligence (AI), rise in liquid biopsy adoption, focus on early stage detection, and expansion of low-dose CT screening programs.

The projected increase in the prevalence of lung cancer is poised to drive the growth of the lung cancer diagnostic and screening market in the foreseeable future. Lung cancer, characterized by symptoms such as coughing, chest pain, and difficulty breathing, is a malignant disease marked by the uncontrolled proliferation of abnormal cells in lung tissues. Diagnostic and screening methods for lung cancer play a crucial role in early detection, utilizing various tests such as incisional biopsy and bronchoscopy. As of January 2023, data from the American Cancer Society indicates approximately 238,340 new cases of lung cancer in the United States, with 127,070 reported deaths. This surge in lung cancer cases underscores the significance of diagnostic and screening measures, thereby fueling the growth of the lung cancer diagnostic and screening market.

The upward trajectory of healthcare expenditures is anticipated to further propel the expansion of the lung cancer diagnostic and screening market. Healthcare expenditures encompass the total costs associated with providing and receiving medical services, treatments, and healthcare-related goods and activities. The implementation of lung cancer diagnostic and screening methods contributes to healthcare expenditures by facilitating early detection, potentially reducing long-term treatment costs, and enhancing patient outcomes. In November 2022, the Canadian Institute for Health Information (CIHI) projected a 0.8% increase in total health spending in Canada, reaching $331 billion in 2022 from $328 billion in 2021. This upward trend in healthcare expenditures is a key driver in the growth of the lung cancer diagnostic and screening market.

Key players in the lung cancer diagnostic and screening market are advancing technologies such as lung cancer tests aimed at enhancing early detection, improving diagnostic accuracy, and enabling personalized treatment strategies for patients at high risk of the disease. These lung cancer tests utilize various methods, including imaging, biomarker analysis, and cytological examinations, to identify the presence of lung cancer. For example, in December 2023, Freenome, a biotechnology company based in the United States, introduced PROACT LUNG. This trial represents a significant advancement in lung cancer screening, potentially leading to earlier detection and improved patient outcomes while addressing current shortcomings in screening practices.

Major players in the lung cancer diagnostics and screening market are strategically focused on the development of blood-based tests that leverage machine learning, specifically whole-genome machine learning. This approach involves applying machine learning algorithms to analyze and interpret comprehensive sets of genetic information, encompassing an organism's entire genome. DELFI Diagnostics Inc., a US-based developer of accessible blood-based tests, exemplified this strategy in October 2023 with the launch of FirstLook Lung. This blood test utilizes whole-genome machine learning to analyze cell-free DNA fragments, enhancing lung cancer screening with an impressive 99.7% negative predictive value (NPV). Designed for routine blood work, the test identifies individuals with potential lung cancer, including those in early stages, aiming to improve population health by addressing low uptake of low-dose computed tomography (LDCT) screening.

In January 2022, RadNet Inc., a US-based radiology company, acquired Aidence BV for an undisclosed amount. This acquisition is anticipated to strengthen RadNet Inc.'s leadership in developing and deploying artificial intelligence (AI) for improved patient care and health. It also accelerates their growth and innovation pipeline, providing automated and integrated AI oncology solutions for clinicians. Aidence BV, based in the Netherlands, is a healthcare technology company with a focus on clinical solutions for lung cancer screening and pulmonary nodule treatment.

Major companies operating in the lung cancer diagnostic and screening market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories Inc., Danaher Corporation, Siemens Healthcare GmbH, FUJIFILM Corporation, Koninklijke Philips N.V., GE Healthcare Bio Sciences AB, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Qiagen Inc., Myriad Genetic Laboratories Inc., NeoGenomics Laboratories Inc., Canon Medical Systems Corporation, OncimmuneHoldings Plc, Broncus Medical Inc., OncoCyte, Riverain Technologies LLC, VisionGate, Foundation Medicine Inc., Biodesix,

North America was the largest region in the lung cancer diagnostic and screening market in 2024. The regions covered in the lung cancer diagnostic and screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lung cancer diagnostic and screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer diagnosis and screening market consists of revenues earned by entities by providing positron emission tomography (PET) scanners, and bronchoscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer diagnosis and screening market also includes sales of products such as liquid biopsy kits, molecular testing kits, and biopsy tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Diagnostic And Screening Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer diagnostic and screening market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer diagnostic and screening ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer diagnostic and screening market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Instruments; Consumables And Accessories
• 2) By Test: Biomarkers Tests; Imaging Test; Biopsy; Blood Test; Other Tests
• 3) By Cancer Type: Non-Small Cell Lung Cancer; Small Cell Lung Cancer
• 4) By End User: Hospital; Independent Diagnostic Laboratories; Diagnostic Imaging Centers; Cancer Research Institutes; Other End-Users
• Subsegments:
• 1) By Instruments: Imaging Devices; Biopsy Devices; Bronchoscopy Systems
• 2) By Consumables And Accessories: Biopsy Needles; Reagents And Assays; Imaging Contrast Agents; Patient Preparation Equipment; Sample Collection Kits; Laboratory Supplies
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; AstraZeneca Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Diagnostic And Screening Market Characteristics

3. Lung Cancer Diagnostic And Screening Market Trends And Strategies

4. Lung Cancer Diagnostic And Screening Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Lung Cancer Diagnostic And Screening Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lung Cancer Diagnostic And Screening PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lung Cancer Diagnostic And Screening Market Growth Rate Analysis
• 5.4. Global Lung Cancer Diagnostic And Screening Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lung Cancer Diagnostic And Screening Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lung Cancer Diagnostic And Screening Total Addressable Market (TAM)

6. Lung Cancer Diagnostic And Screening Market Segmentation

• 6.1. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Instruments
• Consumables And Accessories
• 6.2. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biomarkers Tests
• Imaging Test
• Biopsy
• Blood Test
• Other Tests
• 6.3. Global Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• 6.4. Global Lung Cancer Diagnostic And Screening Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Other End-Users
• 6.5. Global Lung Cancer Diagnostic And Screening Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Devices
• Biopsy Devices
• Bronchoscopy Systems
• 6.6. Global Lung Cancer Diagnostic And Screening Market, Sub-Segmentation Of Consumables And Accessories, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy Needles
• Reagents And Assays
• Imaging Contrast Agents
• Patient Preparation Equipment
• Sample Collection Kits
• Laboratory Supplies

7. Lung Cancer Diagnostic And Screening Market Regional And Country Analysis

• 7.1. Global Lung Cancer Diagnostic And Screening Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lung Cancer Diagnostic And Screening Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Diagnostic And Screening Market

• 8.1. Asia-Pacific Lung Cancer Diagnostic And Screening Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Diagnostic And Screening Market

• 9.1. China Lung Cancer Diagnostic And Screening Market Overview
• 9.2. China Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Diagnostic And Screening Market

• 10.1. India Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Diagnostic And Screening Market

• 11.1. Japan Lung Cancer Diagnostic And Screening Market Overview
• 11.2. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Diagnostic And Screening Market

• 12.1. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Diagnostic And Screening Market

• 13.1. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Diagnostic And Screening Market

• 14.1. South Korea Lung Cancer Diagnostic And Screening Market Overview
• 14.2. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Diagnostic And Screening Market

• 15.1. Western Europe Lung Cancer Diagnostic And Screening Market Overview
• 15.2. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Diagnostic And Screening Market

• 16.1. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Diagnostic And Screening Market

• 17.1. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Diagnostic And Screening Market

• 18.1. France Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Diagnostic And Screening Market

• 19.1. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Diagnostic And Screening Market

• 20.1. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Diagnostic And Screening Market

• 21.1. Eastern Europe Lung Cancer Diagnostic And Screening Market Overview
• 21.2. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Diagnostic And Screening Market

• 22.1. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Diagnostic And Screening Market

• 23.1. North America Lung Cancer Diagnostic And Screening Market Overview
• 23.2. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Diagnostic And Screening Market

• 24.1. USA Lung Cancer Diagnostic And Screening Market Overview
• 24.2. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Diagnostic And Screening Market

• 25.1. Canada Lung Cancer Diagnostic And Screening Market Overview
• 25.2. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Diagnostic And Screening Market

• 26.1. South America Lung Cancer Diagnostic And Screening Market Overview
• 26.2. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Diagnostic And Screening Market

• 27.1. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Diagnostic And Screening Market

• 28.1. Middle East Lung Cancer Diagnostic And Screening Market Overview
• 28.2. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Diagnostic And Screening Market

• 29.1. Africa Lung Cancer Diagnostic And Screening Market Overview
• 29.2. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lung Cancer Diagnostic And Screening Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Diagnostic And Screening Market Competitive Landscape And Company Profiles

• 30.1. Lung Cancer Diagnostic And Screening Market Competitive Landscape
• 30.2. Lung Cancer Diagnostic And Screening Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Diagnostic And Screening Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories Inc.
• 31.2. Danaher Corporation
• 31.3. Siemens Healthcare GmbH
• 31.4. FUJIFILM Corporation
• 31.5. Koninklijke Philips N.V.
• 31.6. GE Healthcare Bio Sciences AB
• 31.7. Quest Diagnostics Incorporated
• 31.8. Agilent Technologies Inc.
• 31.9. Illumina Inc.
• 31.10. Qiagen Inc.
• 31.11. Myriad Genetic Laboratories Inc.
• 31.12. NeoGenomics Laboratories Inc.
• 31.13. Canon Medical Systems Corporation
• 31.14. OncimmuneHoldings Plc
• 31.15. Broncus Medical Inc.

32. Global Lung Cancer Diagnostic And Screening Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Diagnostic And Screening Market

34. Recent Developments In The Lung Cancer Diagnostic And Screening Market

35. Lung Cancer Diagnostic And Screening Market High Potential Countries, Segments and Strategies

• 35.1 Lung Cancer Diagnostic And Screening Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lung Cancer Diagnostic And Screening Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lung Cancer Diagnostic And Screening Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer